AstraZeneca PLC (AZN)
164.77
+3.14
(+1.94%)
USD |
NYSE |
Sep 03, 16:00
162.94
-1.83
(-1.11%)
Pre-Market: 09:27
AstraZeneca Cash from Investing (Quarterly) : -1.856B for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -1.856B |
| December 31, 2025 | -1.501B |
| September 30, 2025 | -2.088B |
| June 30, 2025 | -2.201B |
| March 31, 2025 | -1.32B |
| December 31, 2024 | -1.243B |
| September 30, 2024 | -1.589B |
| June 30, 2024 | -2.985B |
| March 31, 2024 | -2.506B |
| December 31, 2023 | -1.156B |
| September 30, 2023 | -1.295B |
| June 30, 2023 | -587.00M |
| March 31, 2023 | -1.313B |
| December 31, 2022 | -283.00M |
| September 30, 2022 | -1.759B |
| June 30, 2022 | -807.00M |
| March 31, 2022 | -171.00M |
| December 31, 2021 | -1.068B |
| September 30, 2021 | -10.46B |
| June 30, 2021 | -239.00M |
| March 31, 2021 | 531.00M |
| December 31, 2020 | 134.00M |
| September 30, 2020 | -586.00M |
| June 30, 2020 | 139.00M |
| March 31, 2020 | -19.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 41.00M |
| September 30, 2019 | 39.00M |
| June 30, 2019 | -1.153B |
| March 31, 2019 | 292.00M |
| December 31, 2018 | 885.00M |
| September 30, 2018 | -171.00M |
| June 30, 2018 | -184.00M |
| March 31, 2018 | 241.61M |
| December 31, 2017 | -1.688B |
| September 30, 2017 | -378.00M |
| June 30, 2017 | -235.00M |
| March 31, 2017 | -191.00M |
| December 31, 2016 | 568.00M |
| September 30, 2016 | -650.07M |
| June 30, 2016 | -1.070B |
| March 31, 2016 | -2.900B |
| December 31, 2015 | -2.606B |
| September 30, 2015 | -463.00M |
| June 30, 2015 | -697.00M |
| March 31, 2015 | -596.00M |
| December 31, 2014 | -1.553B |
| September 30, 2014 | -581.58M |
| June 30, 2014 | -1.213B |
| March 31, 2014 | -3.823B |
| December 31, 2013 | -1.033B |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| GSK Plc | -1.176B |
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| Novo Nordisk A/S | -2.009B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.420B |
| Cash from Financing (Quarterly) | 266.55M |
| Free Cash Flow | 8.051B |
| Free Cash Flow Per Share (Quarterly) | 0.6037 |
| Free Cash Flow to Equity (Quarterly) | -2.411B |
| Free Cash Flow to Firm (Quarterly) | 2.194B |
| Free Cash Flow Yield | 1.56% |